new molecular entity

A term describing a chemically unique pharmaceutical that has not yet been marketed in the US in any form

new molecular entity

,

NME

A unique, pharmacologically active product that has never previously been synthesized or used to treat disease.
Mentioned in ?
References in periodicals archive ?
Sofpironium bromide, a new molecular entity and "soft" drug, is an anticholinergic medication that blocks the action of acetylcholine activation of sweat glands.
It is a new molecular entity that was rationally designed and developed by UCB.
These projects include the clinical development of three products in Phase 3 and a new molecular entity in Phase 1, preparations for the upcoming release of two products for psoriasis in Europe, one is a biological product and to continue to support the new launchings during 2016 in the United States as well as growth in the aesthetic area.
Despite the odds of a new molecular entity becoming an approved drug being extremely long, the dominant IP is vested in chemical composition of matter.
Andrey Leonov, Chief Executive Officer of Incuron, LLC, commented, "We are excited to start clinical trials with CBLC137, a proprietary new molecular entity.
They, along with efficacy, are critical properties in determining whether a new molecular entity will become a clinical candidate and subsequently, another drug on the market.
Considered a new molecular entity by the FDA, naproxcinod, which is taken orally, is enzymatically cleaved in vivo to release two active metabolites-naproxen and nitric oxide.
We also considered the patient populations in need of additional treatment options, existing treatments and whether this was a new molecular entity.
Tekturna, a new molecular entity (NME), is the first high blood pressure drug approved by FDA that inhibits renin, a kidney enzyme associated with the regulation of blood pressure.
Anthelios SX, which is sponsored by L'Oreal, contains ecamsule, a new molecular entity (NME) compound marketed in Europe and Canada as Mexoryl SX.
At the same time, the new molecular entity is considered to have fewer deleterious peripheral side effects associated with estrogen-like activity.
Offers an overview of the company's new molecular entity pipeline.